Bioshares summit to discuss bypassing big pharma
17 July, 2012 by Dylan Bushell-EmblingA central theme of this week's Bioshares Biotech Summit in New Zealand is the trend of foregoing outlicensing to big pharma in order to bring products to market alone or with a smaller partner.
GI Dynamics extends reach of diabetes treatment
17 July, 2012 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has expanded the reach of its EndoBarrier diabetes treatment to France and to more clinics in its existing markets.
Biotechs undo gains from last quarter
17 July, 2012 by Tim DeanMany Australian biotech stocks have seen a reversal of fortune in the most recent quarter, with market volatility and some disappointing results hampering share prices.
Student volunteer program and excellence awards closing soon
17 July, 2012 by AusBiotechTwo of AusBiotech’s most important student programs to assist bio-students’ linkages with industry are closing soon for 2012.
Recombined virus from vaccines poses no threat to humans
13 July, 2012 by Tim DeanTwo live attenuated vaccines in poultry have recombined to produce a new virulent herpesvirus, although the probability of a similar event in human viruses is vanishingly remote, say scientists.
Movers and Shakers
12 July, 2012 by Dylan Bushell-EmblingAgenix business advisor; AusBiotech board member; Director for new La Trobe institute; OBodies advisory board; Mesoblast director; AHG board switch-up.
Draft NSW Manufacturing Industry Action Plan open for comment
10 July, 2012 by AusBiotechThe NSW Government has published its draft Manufacturing Industry Action Plan and has invited comment on the plan.
GTG ramps up gene patent litigation efforts
10 July, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has cemented its relationship with its intellectual property bulldog, Sheridan Ross, as it seeks to assert its DNA patents in markets outside of the US.
MDI, CSIRO team to cut Penthrox production costs
10 July, 2012 by Dylan Bushell-EmblingThe CSIRO will help MDI improve the production process for homegrown analgesic Penthrox to support the company's EU expansion plans for the product.
Immuron to issue $4.1m worth of options
09 July, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) plans to issue $4.1m worth of options exercisable at $0.04 per share - just under twice the current trading price of the company's shares.
Latest AusBiotech journal features special investment edition
05 July, 2012 by AusBiotechAusBiotech is pleased to announce that the July edition of AusBiotech’s journal, Australasian Biotechnology, is now published, featuring a special investment edition.
Cancer Therapeutics proves concept behind new drug
05 July, 2012 by Dylan Bushell-EmblingCancer Therapeutics has revealed positive preclinical results from a trial of CTx-294886 and that it has produced a new small molecule screening platform.
TGA fee hike under fire from industry
05 July, 2012 by Tim DeanSeveral biotech and pharmaceutical industry associations have banded together to call for the recent TGA fee hike to be wound back.
Sirtex sales defy global economic woes
04 July, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) recorded strong quarterly and full-year growth for dose sales of its SIR-Spheres targeted radioactive liver cancer treatments.
Starpharma accelerates dendrimer program
04 July, 2012 by Dylan Bushell-EmblingStarpharma (ASX:SPL) is researching expanding its dendrimer nanotechnology platform to a wide range of drug classes besides its initial focus on chemotherapeutics.
